MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.82 CNY | -0.23% |
|
-1.55% | +6.52% |
| May. 07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
| Apr. 29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Mabwell (Shanghai) Bioscience Co., Ltd.
Price target over the last 5 years
History of analyst recommendation changes
ef09e0af6e7ee.DMCbY1JoKJvtHAsVV6vZ_gJ9ZI_WxAn_Elx9GX5k3OI.dI70BzMAGsi_eTJXI-qBylE7V92Es3qHUwMHa01V6rpp8cgyahB3rqFNeA~3f00c7afa114815709575abee7a2f810
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.82
CNY
Average target price
35.92
CNY
Spread / Average Target
+3.14%
High Price Target
40
CNY
Spread / Highest target
+14.88%
Low Price Target
31.83
CNY
Spread / Lowest Target
-8.59%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688062 Stock
- Consensus Mabwell (Shanghai) Bioscience Co., Ltd.